Table 4 The comparison of outcome measures in different time periods
| Â | Outcome | Baseline compared to 2nd month | Baseline compared to 6th month | 2nd month compared to 6th month | |||
|---|---|---|---|---|---|---|---|
MD (95% CI) | Multiple Comparison | MD (95% CI) | Multiple Comparison | MD (95% CI) | Multiple Comparison | ||
WOMAC Total | PRP + HA | 18.39 (14.89–21.88) | PRP + HA vs. PRP: NS | 20.00 (15.96–24.05) | PRP + HA vs. PRP: NS | 1.61 (−0.92–4.15) | PRP + HA vs. PRP: NS |
PRP | 17.81 (14.37–21.25) | PRP + HA vs. HA: NS | 19.84 (15.86–23.83) | PRP + HA vs. HA: 0.007 | 2.03 (− 0.46–4.52) | PRP + HA vs. HA: 0.020 | |
HA | 16.03 (12.42–19.65) | PRP vs. HA: NS | 14.21 (10.03–18.39) | PRP vs. HA: 0.022 | −1.83 (−4.45–0.79) | PRP vs. HA: 0.021 | |
Lequesne ADL | PRP + HA | 1.50 (1.03–1.97) | PRP + HA vs. PRP: NS | 1.95 (1.42–2.49) | PRP + HA vs. PRP: NS | 0.45 (0.07–0.83) | PRP + HA vs. PRP: NS |
PRP | 1.25 (0.79–1.71) | PRP + HA vs. HA: NS | 1.53 (1.00–2.06) | PRP + HA vs. HA: < 0.001 | 0.28 (− 0.09–0.65) | PRP + HA vs. HA: 0.012 | |
HA | 1.33 (0.85–1.81) | PRP vs. HA: NS | 0.81 (0.26–1.37) | PRP vs. HA: < 0.001 | − 0.52 (− 0.91 – − 0.13) | PRP vs. HA: 0.001 | |
Lequesne Total | PRP + HA | 3.57 (2.61–4.52) | PRP + HA vs. PRP: NS | 4.37 (3.36–5.38) | PRP + HA vs. PRP: NS | 0.81 (0.10–1.52) | PRP + HA vs. PRP: NS |
PRP | 3.05 (2.10–3.99) | PRP + HA vs. HA: NS | 3.55 (2.55–4.54) | PRP + HA vs. HA: < 0.001 | 0.50 (− 0.20–1.20) | PRP + HA vs. HA: < 0.001 | |
HA | 3.17 (2.18–4.17) | PRP vs. HA: NS | 2.22 (1.18–3.27) | PRP vs. HA: 0.027 | −0.95 (− 1.68 – − 0.21) | PRP vs. HA: 0.012 | |